Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZhijuan LinLLLong LiuYHYan Hong

Discussion

Loading...

Member takes

Overview

Phase II study demonstrates high complete remission rates in advanced follicular lymphoma, suggesting favorable treatment outcomes and safety profile.

Key Points

  • To evaluate the efficacy and safety of Zanubrutinib plus Obinutuzumab in patients with untreated high-tumor-burden follicular lymphoma.
  • Phase II study design with patients having advanced follicular lymphoma
  • Zanubrutinib administered at 160mg BID for 12 cycles
  • Obinutuzumab given on specified days in initial cycles and maintained for 2 years
  • Evaluate primary endpoint of complete remission at 12 months and secondary endpoints including PFS and toxicity
  • 26 patients enrolled with a median age of 56 years
  • High complete remission rate of 80% among patients who underwent at least one post-baseline assessment after Cycle 6
  • 15% experienced Grade 1-2 infusion-related reactions, indicating manageable safety profile
  • 67% of patients who achieved complete remission were MRD negative following treatment

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d459https://doi.org/10.1182/blood-2025-1818
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Zanubrutinib combined with bendamustine and rituximab in previously untreated patients with advanced follicular lymphoma: A prospective, open-label, single-arm phase II clinical study2025
  2. 2Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma2025
  3. 3Efficacy and safety of zanubrutinib combination therapy and monotherapy maintenance in patients with follicular lymphoma: A retrospective single-center analysis2025
  4. 4Efficacy and safety of zanubrutinib, rituximab, and venetoclax combination regimen in previously untreated follicular lymphoma: A Phase II trial from the bbc study2025
  5. 5A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis2025